Evidence map›Paper›PMID 42463944›Full record

ArticleLeukemia2026

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

Jorge E Cortes, Delphine Rea, Michael J Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael Deininger and 14 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jorge E CortesGeorgia Cancer Center at Augusta University, Augusta, GA, USA.ORCID http://orcid.org/0000-0002-8636-1071
Delphine ReaDepartment of Hématologie, Hôpital Saint-Louis, Paris, France.
Michael J MauroMyeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2251-4032
Andreas HochhausHematology/Oncology, Universitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0000-0003-0626-0834
Dong-Wook KimUijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea.ORCID http://orcid.org/0000-0003-3967-4267
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fabian LangDepartment of Medicine, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany.ORCID http://orcid.org/0000-0003-2890-029X
Michael C HeinrichPortland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR, USA.ORCID http://orcid.org/0000-0003-3790-0478
Massimo BrecciaDepartment of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy.ORCID http://orcid.org/0000-0003-1163-6162
Michael DeiningerVersiti Blood Research Institute, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0002-2987-1331
Yeow-Tee GohDepartment of Haematology, Singapore General Hospital, Singapore, Singapore.ORCID http://orcid.org/0000-0002-7069-0997
Jeroen J W M JanssenRadboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0001-9567-1955
Moshe TalpazDivision of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-3361-3981
Valle Gómez García de SoriaHospital Universitario La Princesa, Madrid, Spain.
Philipp le CoutreDepartment of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Francois-Xavier MahonDepartment of Hematology, Institut Bergonié, Bordeaux, France.
Daniel J DeAngeloDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7865-2306
Andrea DamonNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Shruti KapoorNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Gessami Sanchez-OlleNovartis Pharma AG, Basel, Switzerland.
Matthias HochNovartis Pharma AG, Basel, Switzerland.
Nithya AgrawalNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.ORCID http://orcid.org/0000-0003-4279-8324
Sara QuenetNovartis Pharma AG, Basel, Switzerland.
Timothy P HughesSouth Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia. tim.hughes@sahmri.com.ORCID http://orcid.org/0000-0002-0910-3730

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

In chronic myeloid leukemia in chronic phase (CML-CP), BCR::ABL1

Indexed as

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseMutationTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNiacinamidePyrazolesYoung AdultasciminibFusion Proteins, bcr-ablNiacinamidePyrazolesTyrosine Kinase Inhibitors

Identifiers

PMID42463944
PMCPMC13506337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.